Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Clonal hematopoiesis & progression of asymptomatic Waldenström’s macroglobulinemia

Adam Sperling • 13 Jun 2022
EHA 2022
Myelodysplastic Syndromes Rare Diseases Waldenström’s Macroglobulinemia

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a study exploring the impact of clonal hematopoeisis (CH) on patients with Waldenström’s macroglobulinemia (WM). Whilst it was found that CH did not have an impact on patients with symptomatic WM, the presence of CH in patients with WM precursor states led to an increased risk of progression to symptomatic disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Adam Sperling

1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023
1:58
Clonal hematopoiesis in multiple myeloma and implications for therapy
Adam Sperling • 27 Sep 2023
2:05
Novel CAR-T constructs being explored in myeloma: T-Charge platform
Adam Sperling • 27 Sep 2023
1:53
PHE885, a T-Charge manufactured BCMA-directed CAR-T therapy in R/R myeloma
Adam Sperling • 4 Jun 2023

Related Videos

1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals